1 active not recruiting, 1 completed, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Optimized Background Regimen (OBR): new trials by email Literature Review of Optimized Background Regimen (OBR) trials Research Report on Optimized Background Regimen (OBR)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir - HIV-1-infection | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 72 | 2019-11-21 | 2026-10-01 |
| Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV ibalizumab, Optimized Background Regimen (OBR) - HIV | Phase 3 | Completed | TaiMed Biologics Inc. | 40 | 2015-08-01 | 2020-03-19 |
| SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC tipranavir, ritonavir, Optimized Background Regimen (OBR) - HIV Infections | Phase 3 | Terminated | Boehringer Ingelheim | 33 | 2007-02-01 | 2014-06-27 |
HIV Infections (1)
Boehringer Ingelheim (1) · Gilead Sciences (1) · TaiMed Biologics Inc. (1)
United States (3) · Canada (2) · Germany (2) · Italy (2) · Spain (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Dominican Republic (1) · France (1) · Japan (1) · Puerto Rico (1) · South Africa (1) · Thailand (1)
2019 (1)